Cytosorbents (NASDAQ:CTSO) Releases Earnings Results, Beats Estimates By $0.73 EPS

Cytosorbents (NASDAQ:CTSO) announced its earnings results on Thursday, August 6th. The medical research company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.73, Zacks reports. The firm had revenue of $9.63 million for the quarter, compared to analyst estimates of $9.38 million. Cytosorbents had a negative net margin of 48.94% and a negative return on equity of 431.65%.

Here are the key takeaways from Cytosorbents’ conference call:

• Profitability and cash-burn trends improved: Second-quarter gross margin rose to 73%, adjusted EBITDA loss improved 38% year over year, and operating cash burn fell to approximately $200,000 excluding restructuring payments. Management reiterated its expectation of reaching operating cash-flow breakeven in the second half of 2026.
• Revenue remained essentially flat at $9.6 million: Distributor and strategic-partner revenue increased 16% year over year and direct sales outside Germany rose 9%, offset by continued weakness in Germany and Middle East disruptions. The company plans to add three to five German sales representatives through early 2027.
• DrugSorb-ATR still faces regulatory uncertainty: The FDA previously denied the company’s de novo application because the pivotal STAR-T trial missed its primary endpoint, although management said a new clinical trial is not required. Cytosorbents plans to submit additional mechanistic data and real-world evidence, with separate FDA discussions planned for the ticagrelor and DOAC indications.
• Management highlighted favorable DrugSorb-ATR secondary analyses: In the CABG per-protocol population, the severe-bleeding endpoint achieved a statistically significant win ratio of 1.59, while a composite of severe bleeding or more than one liter of chest-tube blood loss showed a reported 58% relative risk reduction. These analyses may support a renewed FDA submission, though they do not eliminate the prior primary-endpoint miss.
• HemoDefend-BGA represents longer-term strategic optionality rather than current revenue: The universal-plasma technology has completed development and received constructive FDA feedback on a potential clinical pathway, but Cytosorbents does not plan to fund clinical trials from its current resources. Progress depends on government funding, partnerships, licensing, or another strategic transaction.

Cytosorbents Price Performance

CTSO stock opened at $5.32 on Wednesday. The stock’s 50 day moving average is $6.99 and its two-hundred day moving average is $9.49. Cytosorbents has a 52-week low of $5.13 and a 52-week high of $20.40. The company has a market capitalization of $16.76 million, a PE ratio of -0.92 and a beta of 1.34. The company has a quick ratio of 0.50, a current ratio of 0.66 and a debt-to-equity ratio of 4.70.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Cytosorbents in a report on Monday, July 6th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $107.50.

Insider Buying and Selling at Cytosorbents

In other news, CEO Phillip Chan bought 200,000 shares of Cytosorbents stock in a transaction on Friday, September 4th. The shares were bought at an average price of $0.35 per share, with a total value of $70,000.00. Following the acquisition, the chief executive officer directly owned 1,944,432 shares in the company, valued at approximately $680,551.20. This represents a 11.47% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 7.80% of the company’s stock.

Cytosorbents Company Profile

CytoSorbents Corporation develops medical devices and blood-purification technologies designed to remove harmful substances from the bloodstream. Its proprietary technology uses porous polymer adsorbent beads that can capture and reduce levels of inflammatory mediators, drugs, toxins and other compounds without selectively removing beneficial blood components.

The company’s principal product, CytoSorb, is used in extracorporeal blood purification applications, including the management of cytokine storms and other inflammatory conditions associated with critical illness, cardiac surgery, trauma and sepsis.